Lara Carlos, De Graeve Diana, Franco Fabian
Department of Economics, University of Antwerp, Antwerp, Belgium.
Department of Economics, University of Antwerp, Antwerp, Belgium.
Value Health Reg Issues. 2018 Dec;17:21-31. doi: 10.1016/j.vhri.2018.01.001. Epub 2018 Apr 5.
The Colombian health authorities introduced the pneumococcal conjugated vaccine and the seasonal influenza vaccine into the national immunization schedule for children in 2009 and 2007, respectively. Despite this, the health authorities continue to be concerned about the high economic and disease burden among children from low-income households caused by these vaccine-preventable diseases.
We built a Markov deterministic cohort model to evaluate five consecutive cohorts across four alternative situations: 1) no vaccination; 2) vaccination with the 10-valent pneumococcal conjugate vaccine (PCV10 vaccine); 3) vaccination with the trivalent inactivated vaccine (TIV) annually; and 4) combined vaccination with PCV10 vaccine and TIV.
The introduction of PCV10 vaccine and TIV and their combined use in particular would be highly cost-effective in comparison to no vaccination. For the combined vaccination with PCV10 vaccine and TIV, the incremental cost-effectiveness ratio would be $1,280 per disability-adjusted life-year (DALY) averted, the total incremental cost of the vaccination program would be $776,800, and it would avert four deaths and 332 DALYs for the five cohorts.
The introduction of PCV10 vaccine and TIV would be highly cost-effective from a public, direct medical health care perspective. Despite these results, we have not observed decreases in severity or hospitalizations. Our findings highlight the need for further studies of the immunization campaign indicators and socioeconomic indicators for this low-income community.
哥伦比亚卫生当局分别于2009年和2007年将肺炎球菌结合疫苗和季节性流感疫苗纳入国家儿童免疫规划。尽管如此,卫生当局仍对这些疫苗可预防疾病给低收入家庭儿童带来的高经济和疾病负担感到担忧。
1)从公共直接医疗保健角度评估哥伦比亚一个低收入地区5岁以下补贴儿童的四种疫苗接种策略的潜在健康结果。2)进行单变量、多变量和概率敏感性分析,以评估这些结果的稳健性。
我们构建了一个马尔可夫确定性队列模型,以评估四种替代情况下的五个连续队列:1)不接种疫苗;2)接种10价肺炎球菌结合疫苗(PCV10疫苗);3)每年接种三价灭活疫苗(TIV);4)联合接种PCV10疫苗和TIV。
与不接种疫苗相比,引入PCV10疫苗和TIV,尤其是联合使用,具有很高的成本效益。对于联合接种PCV10疫苗和TIV,每避免一个伤残调整生命年(DALY)的增量成本效益比为1280美元,疫苗接种计划的总增量成本为776,800美元,并且对于五个队列可避免4例死亡和332个DALY。
从公共直接医疗保健角度来看,引入PCV10疫苗和TIV具有很高的成本效益。尽管有这些结果,但我们并未观察到严重程度或住院率的下降。我们的研究结果强调了对这个低收入社区的免疫活动指标和社会经济指标进行进一步研究的必要性。